Neuphoria Therapeutics Inc., listed as NEUP on Nasdaq, has successfully completed the scheme of arrangement to facilitate Bionomics Limited's move from Australia to the United States. Neuphoria will now act as the primary parent company for Bionomics Limited, with the implementation taking place on December 23, 2024 in New York and December 24, 2024 in Sydney. This move marks a significant transition in the structures of both companies, representing a strategic shift in their operations.